Annual Cash & Cash Equivalents
$248.11 M
-$3.17 M-1.26%
December 31, 2021
Summary
- As of February 9, 2025, ALBO annual cash & cash equivalents is $248.11 million, with the most recent change of -$3.17 million (-1.26%) on December 31, 2021.
- During the last 3 years, ALBO annual cash & cash equivalents has risen by +$84.22 million (+51.39%).
Performance
ALBO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$222.48 M
+$41.51 M+22.93%
September 30, 2022
Summary
- As of February 9, 2025, ALBO quarterly cash and cash equivalents is $222.48 million, with the most recent change of +$41.51 million (+22.93%) on September 30, 2022.
- Over the past year, ALBO quarterly cash and cash equivalents has dropped by -$40.14 million (-15.28%).
Performance
ALBO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ALBO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.3% | -15.3% |
| 3 y3 years | +51.4% | +55.9% |
| 5 y5 years | +366.1% | +289.8% |
ALBO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | -10.3% | -18.7% |
| 5 y | 5-year | -1.3% | -46.9% | -20.2% | -40.7% |
| alltime | all time | -1.3% | -99.9% | -20.2% | -99.8% |
Albireo Pharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $222.48 M(+22.9%) |
| Jun 2022 | - | $180.97 M(-16.5%) |
| Mar 2022 | - | $216.66 M(-12.7%) |
| Dec 2021 | $248.11 M(-1.3%) | $248.11 M(-5.5%) |
| Sep 2021 | - | $262.61 M(+41.0%) |
| Jun 2021 | - | $186.29 M(-14.2%) |
| Mar 2021 | - | $217.08 M(-13.6%) |
| Dec 2020 | $251.27 M(+90.6%) | $251.27 M(-9.8%) |
| Sep 2020 | - | $278.69 M(+83.3%) |
| Jun 2020 | - | $152.02 M(+1.0%) |
| Mar 2020 | - | $150.51 M(+14.2%) |
| Dec 2019 | $131.84 M(-19.6%) | $131.84 M(-7.6%) |
| Sep 2019 | - | $142.67 M(-9.5%) |
| Jun 2019 | - | $157.72 M(+4.9%) |
| Mar 2019 | - | $150.34 M(-8.3%) |
| Dec 2018 | $163.88 M(+207.9%) | $163.88 M(-5.6%) |
| Sep 2018 | - | $173.60 M(-5.3%) |
| Jun 2018 | - | $183.23 M(-5.0%) |
| Mar 2018 | - | $192.92 M(+262.4%) |
| Dec 2017 | $53.23 M(+77.8%) | $53.23 M(-6.7%) |
| Sep 2017 | - | $57.07 M(-8.8%) |
| Jun 2017 | - | $62.60 M(+210.8%) |
| Mar 2017 | - | $20.14 M(-29.8%) |
| Dec 2016 | $29.93 M(+4.3%) | - |
| Sep 2016 | - | $28.68 M(-7.5%) |
| Sep 2016 | $28.68 M(-29.8%) | - |
| Jun 2016 | - | $31.02 M(-7.2%) |
| Mar 2016 | - | $33.43 M(-9.5%) |
| Dec 2015 | - | $36.93 M(-9.6%) |
| Sep 2015 | $40.84 M(+66.1%) | $40.84 M(-7.9%) |
| Jun 2015 | - | $44.35 M(+149.8%) |
| Mar 2015 | - | $17.75 M(-10.0%) |
| Dec 2014 | - | $19.73 M(-19.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2014 | $24.59 M(-38.2%) | $24.59 M(+0.4%) |
| Jun 2014 | - | $24.48 M(-14.7%) |
| Mar 2014 | - | $28.69 M(-18.6%) |
| Dec 2013 | - | $35.24 M(-11.4%) |
| Sep 2013 | $39.78 M(+1.9%) | $39.78 M(-6.1%) |
| Jun 2013 | - | $42.38 M(+51.9%) |
| Mar 2013 | - | $27.90 M(-18.6%) |
| Dec 2012 | - | $34.28 M(-12.2%) |
| Sep 2012 | $39.05 M(+0.9%) | $39.05 M(-10.6%) |
| Jun 2012 | - | $43.69 M(+46.4%) |
| Mar 2012 | - | $29.84 M(-14.9%) |
| Dec 2011 | - | $35.05 M(-9.4%) |
| Sep 2011 | $38.70 M(+68.8%) | $38.70 M(-7.9%) |
| Jun 2011 | - | $42.00 M(+139.2%) |
| Mar 2011 | - | $17.56 M(-21.2%) |
| Dec 2010 | - | $22.29 M(-2.8%) |
| Sep 2010 | $22.92 M(-58.0%) | $22.92 M(+28.4%) |
| Jun 2010 | - | $17.85 M(-45.4%) |
| Mar 2010 | - | $32.72 M(-17.3%) |
| Dec 2009 | - | $39.55 M(-27.6%) |
| Sep 2009 | $54.64 M(-15.6%) | $54.64 M(-14.0%) |
| Jun 2009 | - | $63.57 M(+5.9%) |
| Mar 2009 | - | $60.02 M(-4.6%) |
| Dec 2008 | - | $62.95 M(-2.8%) |
| Sep 2008 | $64.73 M(-19.1%) | $64.73 M(-8.7%) |
| Jun 2008 | - | $70.87 M(-34.3%) |
| Mar 2008 | - | $107.88 M(+48.3%) |
| Dec 2007 | - | $72.77 M(-9.1%) |
| Sep 2007 | $80.02 M(+356.3%) | $80.02 M(-7.3%) |
| Jun 2007 | - | $86.36 M(+668.5%) |
| Mar 2007 | - | $11.24 M(-22.8%) |
| Dec 2006 | - | $14.56 M(-17.0%) |
| Sep 2006 | $17.54 M(+4666.0%) | $17.54 M(+4666.0%) |
| Sep 2005 | $368.00 K | $368.00 K |
FAQ
- What is Albireo Pharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Albireo Pharma?
- What is Albireo Pharma annual cash & cash equivalents year-on-year change?
- What is Albireo Pharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Albireo Pharma?
- What is Albireo Pharma quarterly cash and cash equivalents year-on-year change?
What is Albireo Pharma annual cash & cash equivalents?
The current annual cash & cash equivalents of ALBO is $248.11 M
What is the all time high annual cash & cash equivalents for Albireo Pharma?
Albireo Pharma all-time high annual cash & cash equivalents is $251.27 M
What is Albireo Pharma annual cash & cash equivalents year-on-year change?
Over the past year, ALBO annual cash & cash equivalents has changed by -$3.17 M (-1.26%)
What is Albireo Pharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ALBO is $222.48 M
What is the all time high quarterly cash and cash equivalents for Albireo Pharma?
Albireo Pharma all-time high quarterly cash and cash equivalents is $278.69 M
What is Albireo Pharma quarterly cash and cash equivalents year-on-year change?
Over the past year, ALBO quarterly cash and cash equivalents has changed by -$40.14 M (-15.28%)